Transgene strengthens its balance sheet by converting part of TSGH’s current account advance into shares – 07/30/2024 at 9:25 p.m.

This press release may not be published, transmitted or broadcast or distributed, directly or indirectly, in or into the United States, Canada, Australia or Japan.

Strasbourg, France, July 30, 2024, 9:00 p.m. CET – Transgene (Euronext Paris: TNG), a biotechnology company that designs and develops viral-based cancer immunotherapies, announces the conversion into shares of €32,999,999.57 of debt, drawn on the current account advance granted by its majority shareholder TSGH (a subsidiary of Institut Mérieux), in accordance with the terms of the agreement signed with TSGH for the first time in 2023. As a result, TSGH’s shareholding in Transgene will increase from 59.7% to 69.1%.

…/…